163 related articles for article (PubMed ID: 34655887)
1. Unique challenges and outcomes of young women with breast cancers from a tertiary care cancer centre in India.
Bajpai J; Ventrapati P; Joshi S; Wadasadawala T; Rath S; Pathak R; Nandhana R; Mohanty S; Chougle Q; Engineer M; Abraham N; Ghosh J; Nair N; Gulia S; Popat P; A P; Sheth T; Desai S; Thakur M; Rangrajan V; Parmar V; Sarin R; Gupta S; Badwe RA
Breast; 2021 Dec; 60():177-184. PubMed ID: 34655887
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
Kokka F; Bryant A; Brockbank E; Powell M; Oram D
Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
[TBL] [Abstract][Full Text] [Related]
5. The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.
Das U; Lakshmaiah KC; Govind Babu K; Suresh TM; Lokanatha D; Jacob L; Babu S
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1777-82. PubMed ID: 24894013
[TBL] [Abstract][Full Text] [Related]
6. Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology.
Rais G; Raissouni S; Aitelhaj M; Rais F; Naciri S; Khoyaali S; Abahssain H; Bensouda Y; Khannoussi B; Mrabti H; Errihani H
BMC Womens Health; 2012 Oct; 12():35. PubMed ID: 23039971
[TBL] [Abstract][Full Text] [Related]
7. Platinum-based chemotherapy for early triple-negative breast cancer.
Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
Cochrane Database Syst Rev; 2023 Sep; 9(9):CD014805. PubMed ID: 37681577
[TBL] [Abstract][Full Text] [Related]
8. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.
Koca E; Kuzan TY; Dizdar O; Babacan T; Sahin I; Ararat E; Altundag K
Med Oncol; 2013; 30(3):615. PubMed ID: 23729267
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort.
Bajpai J; Kashyap L; Vallathol DH; Das A; Singh M; Pathak R; Rath S; Sekar A; Mohanta S; Reddy A; Joshi S; Nandhana R; Ravind R; Wadasadawala T; Nair N; Ghosh J; Parmar V; Gulia S; Desai S; Shet T; Thakur M; Patil A; Sarin R; Gupta S; Badwe R
Breast; 2022 Jun; 63():77-84. PubMed ID: 35334242
[TBL] [Abstract][Full Text] [Related]
11. Survival outcomes with 12 weeks of adjuvant or neoadjuvant trastuzumab in breast cancer.
Ghosh J; Joy Phillip DS; Ghosh J; Bajpai J; Gulia S; Parmar V; Nair N; Joshi S; Sarin R; Budrukkar AN; Wadasadawala T; Desai SB; Shet T; Patil A; Sawant SP; Dhir AA; Kembhavi S; Popat P; Hawaldar R; Kembhavi Y; Perumal P; Banavali SD; Badwe RA; Gupta S
Indian J Cancer; 2022; 59(3):387-393. PubMed ID: 33753616
[TBL] [Abstract][Full Text] [Related]
12. Stage-to-stage comparison of neoadjuvant chemotherapy versus adjuvant chemotherapy in pathological lymph node positive breast cancer patients.
Lee NK; Shin KH; Park IH; Lee KS; Ro J; Jung SY; Lee S; Kim SW; Kim TH; Kim JY; Kang HS; Cho KH
Jpn J Clin Oncol; 2012 Nov; 42(11):995-1001. PubMed ID: 22911001
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Women with Non-Metastatic Triple-Negative Breast Cancer in Oman: A single-centre experience.
Kumar S; Furrukh M; Al-Baimani K; Al-Ajmi A; Burney IA; Al-Moundhri MS
Sultan Qaboos Univ Med J; 2019 Aug; 19(3):e209-e216. PubMed ID: 31728218
[TBL] [Abstract][Full Text] [Related]
14. Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation.
Letourneau JM; Wald K; Sinha N; Juarez-Hernandez F; Harris E; Cedars MI; McCulloch CE; Dolezal M; Chien AJ; Rosen MP
Cancer; 2020 Feb; 126(3):487-495. PubMed ID: 31639215
[TBL] [Abstract][Full Text] [Related]
15. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
[TBL] [Abstract][Full Text] [Related]
17. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
Chien AJ; Chambers J; Mcauley F; Kaplan T; Letourneau J; Hwang J; Kim MO; Melisko ME; Rugo HS; Esserman LJ; Rosen MP
Breast Cancer Res Treat; 2017 Aug; 165(1):151-159. PubMed ID: 28503722
[TBL] [Abstract][Full Text] [Related]
18. The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival.
Greer AC; Lanes A; Poorvu PD; Kennedy P; Thomas AM; Partridge AH; Ginsburg ES
Cancer; 2021 Oct; 127(20):3872-3880. PubMed ID: 34161610
[TBL] [Abstract][Full Text] [Related]
19. A Multicenter Study of the Impact of Body Mass Index (BMI) on the incidence of Pathologic Complete Response (pCR) Among Saudi Patients with locally advanced Breast cancer (LABC) post Neoadjuvant Chemotherapy (NAC).
Al-Saleh K; Abd El-Aziz N; Ali A; Abo Zeed W; Salah T; Elsamany S; Rasmy A; El Farargy O; Husain S; Al-Rikabi A; Alsaeed E; Aldiab A; Abd El-Warith A
Gulf J Oncolog; 2019 May; 1(30):33-42. PubMed ID: 31242980
[TBL] [Abstract][Full Text] [Related]
20. The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB.
Liu J; Mao K; Jiang S; Jiang W; Chen K; Kim BY; Liu Q; Jacobs LK
Oncotarget; 2016 Apr; 7(17):24848-59. PubMed ID: 26709538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
